2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Vinuesa, S. G. Articles by Luño, J. Search for Related Content PubMed PubMed Citation Articles by de Vinuesa, S. G. Articles by Luño, J.

Insulin Resistance, Inflammatory Biomarkers, and Adipokines in Patients with Chronic Kidney Disease: Effects of Angiotensin II Blockade

Soledad García de Vinuesa^*, Marian Goicoechea^*, Julia Kanter^*, Marta Puerta^*, Victoria Cachofeiro, Vicente Lahera, Francisco Gómez-Campderá^* and José Luño^*

^* Department of Nephrology, Hospital General Universitario Gregorio Marañón, and Department of Physiology, Universidad Complutense de Madrid, Madrid, Spain

Address correspondence to: Dr. Soledad García de Vinuesa, Department of Nephrology, Hospital General Universitario Gregorio Marañón, C/Dr. Esquerdo 47, 28007, Madrid, Spain. Phone: +34915868319; Fax: +34915868318; E-mail: solgdevinuesa{at}terra.es

Patients with chronic kidney disease (CKD) present a high prevalence of insulin resistance (IR). Some studies suggest that angiotensin II may influence some cellular pathways that contribute to the pathogenesis of IR and stimulate the release of proinflammatory cytokines. Fifty-two patients who had stages 3 and 4 CKD and no diabetes were administered an angiotensin receptor blocker (ARB), olmesartan (40 mg), for 16 wk. Before and after ARB treatment, metabolic and inflammatory parameters and adipokines were measured. IR was calculated by Homeostasis Model Assessment (HOMA) index. Baseline data were compared with data that were obtained from 25 healthy control individuals of similar age and normal renal function. Compared with control subjects, patients with CKD presented significantly higher BP and waist circumference, higher triglycerides and lower HDL levels, higher insulin levels, and higher mean HOMA index (6.0 ± 2.7 versus 2.9 ± 2.2 µU/ml x mmol/L; P < 0.001). In addition, patients with CKD had increased levels of high-sensitivity C-reactive protein, TNF-, and IL-6. In patients with CKD, leptin was positively correlated to abdominal obesity, insulin levels, and IL-6, and adiponectin was inversely correlated to abdominal obesity and insulin levels. Olmesartan treatment resulted in a significant decrease of BP, urinary protein excretion, plasma glucose (99 ± 16 versus 92 ± 14 mg/dl; P < 0.05), insulin (23.1 ± 8.8 versus 19.9 ± 9; P < 0.05), HOMA index (6.0 ± 2.7 versus 4.7 ± 2.8; P < 0.05), and glycated hemoglobin (5.33 ± 0.58 versus 4.85 ± 0.81%; P < 0.01). At the same time, there was a significant reduction of high-sensitivity C-reactive protein levels, from 4.45 mg/L (2.45 to 9.00) to 3.55 mg/L (1.80 to 5.40; P < 0.05) and fibrinogen (412 ± 100 versus 370 ± 105 mg/dl; P < 0.05). There were no significant differences in adipokine levels after olmesartan treatment. These data demonstrate that patients with CKD have a high prevalence of IR, metabolic syndrome, and chronic inflammation and that the administration of the ARB olmesartan improves IR and inflammation markers in these patients. Plasma adipokine levels that are related to several metabolic risk factors in patients with CKD were not modified by ARB therapy.

This article has been cited by other articles:

				S.-C. Hung and D.-C. Tarng Adiposity and insulin resistance in nondiabetic hemodialysis patients: effects of high energy supplementation Am. J. Clinical Nutrition, July 1, 2009; 90(1): 64 - 69. [Abstract] [Full Text] [PDF]

				L. L. Guo, Y. Pan, and H. M. Jin Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1876 - 1883. [Abstract] [Full Text] [PDF]

				G. Wong, A. Hayen, J. R. Chapman, A. C. Webster, J. J. Wang, P. Mitchell, and J. C. Craig Association of CKD and Cancer Risk in Older People J. Am. Soc. Nephrol., June 1, 2009; 20(6): 1341 - 1350. [Abstract] [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673